Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Understanding the duality of uterine leiomyomas and leiomyosarcomas, which molecular features are indications of a sinister transformation?

EF 2023-24

Résumé
Uterine leiomyoma (uLM) is the most common benign uterine tumor in women, reaching an incidence of 70-80%1–3. Uterine leiomyosarcoma (uLMS) is a highly aggressive rare soft tissue sarcoma comprising only 1% of uterine malignancies and comes with poor prognosis if not properly diagnosed1,2,4,5. Accurately diagnosing tumors of the uterine smooth muscle poses a challenge as there are indistinguishable similarities in the symptoms and the histology of benign uLM and malignant uLMS1,6. Due to diagnostic difficulties, decision-making regarding treatment is challenging, as overtreatment for malignancy can result in unnecessary hysterectomies, while undertreatment and delay in cancer diagnosis, will also lead to poor outcomes. This proposal aims to identify candidate biomarkers using the available clinical, genomic, transcriptomic, and histological data for uLM (n=55) and uLMS (n=28) to aid in the prognostication of this currently indistinguishable spectrum of uterine smooth muscle tumors. This data will also provide molecular insight into the heterogenous, indeterminate clusters of uLM and uLMS that exist both within individual tumors and between current clustering analyses2,5. Differentially expressed pathway analysis can further support the understanding of each tumor’s molecular dependencies. Additionally, identifying where or if secondary mutational hits occur, they can be used as risk factors for a tumors potential to undergo malignant transformation. Having effective and accurate biomarkers as prognostic risk factors is critical for the treatment of these tumors as it reduces morbidity for patients and helps to prevent overtreatment while limiting the risk of recurrent malignancy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506550
Name
Williams Megan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding the duality of uterine leiomyomas and leiomyosarcomas, which molecular features are indications of a sinister transformation?
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Benign Neoplasm; Biomarker(S); Rare Cancer; Transcriptomics; Uterine Leiomyoma; Uterine Leiomyosarcoma; Whole Genome Sequencing
Abstract
Uterine leiomyoma (uLM) is the most common benign uterine tumor in women, reaching an incidence of 70-80%1–3. Uterine leiomyosarcoma (uLMS) is a highly aggressive rare soft tissue sarcoma comprising only 1% of uterine malignancies and comes with poor prognosis if not properly diagnosed1,2,4,5. Accurately diagnosing tumors of the uterine smooth muscle poses a challenge as there are indistinguishable similarities in the symptoms and the histology of benign uLM and malignant uLMS1,6. Due to diagnostic difficulties, decision-making regarding treatment is challenging, as overtreatment for malignancy can result in unnecessary hysterectomies, while undertreatment and delay in cancer diagnosis, will also lead to poor outcomes. This proposal aims to identify candidate biomarkers using the available clinical, genomic, transcriptomic, and histological data for uLM (n=55) and uLMS (n=28) to aid in the prognostication of this currently indistinguishable spectrum of uterine smooth muscle tumors. This data will also provide molecular insight into the heterogenous, indeterminate clusters of uLM and uLMS that exist both within individual tumors and between current clustering analyses2,5. Differentially expressed pathway analysis can further support the understanding of each tumor’s molecular dependencies. Additionally, identifying where or if secondary mutational hits occur, they can be used as risk factors for a tumors potential to undergo malignant transformation. Having effective and accurate biomarkers as prognostic risk factors is critical for the treatment of these tumors as it reduces morbidity for patients and helps to prevent overtreatment while limiting the risk of recurrent malignancy.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Williams, Megan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~